FENC

13.0902.68%
MM

Marco Maria Brughera

Independent Director

Dr. Marco Maria Brughera, DVM, has been an Independent Director of Fennec Pharmaceuticals Inc. since August 11, 2016. Dr. Brughera joined the Fennec Pharmaceuticals Inc. on August 11, 2016. He was the Chief Executive Officer of Leadiant Biosciences SpA since January 2011. Dr. Brughera was the Chief Executive Officer/Global Head at Sigma-Tau Pharma Limited UK. Dr. Brughera was the Managing Director of Corporate Research & Development at Sigma-Tau Group since joining in 2011 and was its Chief Executive Officer and Global Head of the Rare Disease Business Unit. At Sigma-Tau, he managed the global R&D portfolio including several programs in research, preclinical, clinical and registration stages. He was the Chairman and President of Sigma-Tau Pharmaceuticals Inc. and Sigma-Tau Research. He drove the commercial revival of a lead oncology product line resulting in its successful sale for a total of around 900M. He also successfully out-licensed the Defibrotide US rights to Jazz Pharmaceuticals. He has experience and management in research and development and operations in the healthcare industry. Dr. Brughera has wide-spread experience and knowledge in pharmaceutical drug development in international companies. He joining Sigma-Tau in 2011 as Managing Director of its Corporate R&D Division. From 2004 to 2010, he served as the Vice President of Preclinical Development at Nerviano Medical Sciences (NMS), a pharmaceutical oncology-focused integrated discovery and development company. He took charge of Sigma-Tau’s Rare Disease Franchise in October 2012. He also served as the Managing Director at Accelera, an independent contract research organization with the NMS Group. From 1999 to 2004, he held several senior level positions in the areas of discovery and development toxicology with Pharmacia and Pfizer. He currently serves on the Board of Exelead and Naicons. Prior to 1999, he held various positions at Pharmacia & Upjohn and Farmitalia Carlo Erba SpA, an Italian pharmaceutical company. He served as a Non Executive Director at Lee's Pharmaceutical Holdings Ltd. since December 29, 2014 until December 29, 2017. He served as Director of Soligenix, Inc. from October 21, 2013 until September 2018. He serves on the Board of Biopharmaceutical Company. He served as a Member of the Board of Directors at Gentium S.p.A from December 2011 to January 24, 2014. He has authored more than 60 publications. He is a European Registered Toxicologist. Dr. Brughera earned his Degree in Veterinary Medicine from the University of Milan and accreditations from institutions including the Thunderbird School of Global Management.

Positions